SAMHSA encourages physicians, physician assistants, nurse practitioners, pharmacists,
other Staff in Opioid Treatment Programs (OTPs) and DATA-Waived Physicians to utilize State Prescription Drug Monitoring
Programs (PDMPs) as an additional resource to maximize safety of patient care pursuant to applicable state guidelines.
The illicit use of prescription drugs (i.e. opioids, stimulants, and sedatives) is a major public health problem. In addition, prescription
drug issues affect patients in OTPs. Click here to read the letter.